Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BAY 2701250 in Healthy Men
NCT06048120Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Therapeutic Proteins, Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BAY2701250 in pulmonary hypertension due to left heart disease (PH-LHD) (2 arms), sponsored by Bayer. Primary endpoint: Treatment-emergent adverse events up to 46 days. Started Sep 2023; status: completed.
02
Drugs
BAY2701250
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)
Beyond the preview
Go deeper on NCT06048120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048120.